254 related articles for article (PubMed ID: 26937398)
1. Muscle imaging data in late-onset Pompe disease reveal a correlation between the pre-existing degree of lipomatous muscle alterations and the efficacy of long-term enzyme replacement therapy.
Gruhn KM; Heyer CM; Güttsches AK; Rehmann R; Nicolas V; Schmidt-Wilcke T; Tegenthoff M; Vorgerd M; Kley RA
Mol Genet Metab Rep; 2015 Jun; 3():58-64. PubMed ID: 26937398
[TBL] [Abstract][Full Text] [Related]
2. Effects of short-to-long term enzyme replacement therapy (ERT) on skeletal muscle tissue in late onset Pompe disease (LOPD).
Ripolone M; Violano R; Ronchi D; Mondello S; Nascimbeni A; Colombo I; Fagiolari G; Bordoni A; Fortunato F; Lucchini V; Saredi S; Filosto M; Musumeci O; Tonin P; Mongini T; Previtali S; Morandi L; Angelini C; Mora M; Sandri M; Sciacco M; Toscano A; Comi GP; Moggio M
Neuropathol Appl Neurobiol; 2018 Aug; 44(5):449-462. PubMed ID: 28574618
[TBL] [Abstract][Full Text] [Related]
3. Follow-up of late-onset Pompe disease patients with muscle magnetic resonance imaging reveals increase in fat replacement in skeletal muscles.
Nuñez-Peralta C; Alonso-Pérez J; Llauger J; Segovia S; Montesinos P; Belmonte I; Pedrosa I; Montiel E; Alonso-Jiménez A; Sánchez-González J; Martínez-Noguera A; Illa I; Díaz-Manera J
J Cachexia Sarcopenia Muscle; 2020 Aug; 11(4):1032-1046. PubMed ID: 32129012
[TBL] [Abstract][Full Text] [Related]
4. Newborn screening for Pompe disease in Italy: Long-term results and future challenges.
Gragnaniello V; Pijnappel PWWM; Burlina AP; In 't Groen SLM; Gueraldi D; Cazzorla C; Maines E; Polo G; Salviati L; Di Salvo G; Burlina AB
Mol Genet Metab Rep; 2022 Dec; 33():100929. PubMed ID: 36310651
[TBL] [Abstract][Full Text] [Related]
5. Study of the effect of anti-rhGAA antibodies at low and intermediate titers in late onset Pompe patients treated with ERT.
Fernández-Simón E; Carrasco-Rozas A; Gallardo E; González-Quereda L; Alonso-Pérez J; Belmonte I; Pedrosa-Hernández I; Montiel E; Segovia S; Suárez-Calvet X; Llauger J; Mayos M; Illa I; Barba-Romero MA; Barcena J; Paradas C; Carzorla MR; Creus C; Coll-Cantí J; Díaz M; Domínguez C; Fernández-Torrón R; García-Antelo MJ; Grau JM; López de Munáin A; Martínez-García FA; Morgado Y; Moreno A; Morís G; Muñoz-Blanco MA; Nascimento A; Parajuá-Pozo JL; Querol L; Rojas R; Robledo-Strauss A; Rojas-Marcos Í; Salazar JA; Usón M; Díaz-Manera J
Mol Genet Metab; 2019; 128(1-2):129-136. PubMed ID: 31378569
[TBL] [Abstract][Full Text] [Related]
6. Long-term exposure to Myozyme results in a decrease of anti-drug antibodies in late-onset Pompe disease patients.
Masat E; Laforêt P; De Antonio M; Corre G; Perniconi B; Taouagh N; Mariampillai K; Amelin D; Mauhin W; Hogrel JY; Caillaud C; Ronzitti G; Puzzo F; Kuranda K; Colella P; Mallone R; Benveniste O; Mingozzi F;
Sci Rep; 2016 Nov; 6():36182. PubMed ID: 27812025
[TBL] [Abstract][Full Text] [Related]
7. Clinical and molecular aspects of 30 patients with late-onset Pompe disease (LOPD): unusual features and response to treatment.
Montagnese F; Barca E; Musumeci O; Mondello S; Migliorato A; Ciranni A; Rodolico C; De Filippi P; Danesino C; Toscano A
J Neurol; 2015; 262(4):968-78. PubMed ID: 25673129
[TBL] [Abstract][Full Text] [Related]
8. Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: The EMBASSY Study.
van der Ploeg A; Carlier PG; Carlier RY; Kissel JT; Schoser B; Wenninger S; Pestronk A; Barohn RJ; Dimachkie MM; Goker-Alpan O; Mozaffar T; Pena LD; Simmons Z; Straub V; Guglieri M; Young P; Boentert M; Baudin PY; Wens S; Shafi R; Bjartmar C; Thurberg BL
Mol Genet Metab; 2016 Sep; 119(1-2):115-23. PubMed ID: 27473031
[TBL] [Abstract][Full Text] [Related]
9. Effect of enzyme replacement therapy in late onset Pompe disease: open pilot study of 48 weeks follow-up.
Park JS; Kim HG; Shin JH; Choi YC; Kim DS
Neurol Sci; 2015 Apr; 36(4):599-605. PubMed ID: 25388776
[TBL] [Abstract][Full Text] [Related]
10. Muscle Proteomic Profile before and after Enzyme Replacement Therapy in Late-Onset Pompe Disease.
Moriggi M; Capitanio D; Torretta E; Barbacini P; Bragato C; Sartori P; Moggio M; Maggi L; Mora M; Gelfi C
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799647
[TBL] [Abstract][Full Text] [Related]
11. Comparison of recent pivotal recommendations for the diagnosis and treatment of late-onset Pompe disease using diagnostic nodes-the Pompe disease burden scale.
Hundsberger T; Schoser B; Leupold D; Rösler KM; Putora PM
J Neurol; 2019 Aug; 266(8):2010-2017. PubMed ID: 31104135
[TBL] [Abstract][Full Text] [Related]
12. Function, structure and quality of striated muscles in the lower extremities in patients with late onset Pompe Disease-an MRI study.
Vaeggemose M; Mencagli RA; Hansen JS; Dräger B; Ringgaard S; Vissing J; Andersen H
PeerJ; 2021; 9():e10928. PubMed ID: 33996274
[TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy of the enzyme replacement therapy in patients with late-onset Pompe disease: a systematic review and a meta-analysis.
Sarah B; Giovanna B; Emanuela K; Nadi N; Josè V; Alberto P
J Neurol; 2022 Feb; 269(2):733-741. PubMed ID: 33851281
[TBL] [Abstract][Full Text] [Related]
14. Albuterol as an adjunctive treatment to enzyme replacement therapy in infantile-onset Pompe disease.
Chien YH; Hwu WL; Lee NC; Tsai FJ; Koeberl DD; Tsai WH; Chiu PC; Chang CL
Mol Genet Metab Rep; 2017 Jun; 11():31-35. PubMed ID: 28480166
[TBL] [Abstract][Full Text] [Related]
15. White matter lesions in treated late onset Pompe disease are not different to matched controls.
Schneider I; Hensel O; Zierz S
Mol Genet Metab; 2019 Jun; 127(2):128-131. PubMed ID: 31153821
[TBL] [Abstract][Full Text] [Related]
16. Enzymatic replacement therapy in patients with late-onset Pompe disease - 6-Year follow up.
Witkowski G; Konopko M; Rola R; Ługowska A; Ryglewicz D; Sienkiewicz-Jarosz H
Neurol Neurochir Pol; 2018 Aug; 52(4):465-469. PubMed ID: 29803406
[TBL] [Abstract][Full Text] [Related]
17. Bioimpedance Phase Angle as a Prognostic Tool in Late-Onset Pompe Disease: A Single-Centre Prospective Study With a 15-year Follow-Up.
Ravaglia S; de Giuseppe R; Carlucci A; Jehne S; Crescimanno G; Ahmad L; Paoletti M; Clemente G; Pichiecchio A; Bazzano R; Cirio S; Valente EM; Danesino C; De Filippi P; Tartara A; Cena H
Front Cell Dev Biol; 2022; 10():793566. PubMed ID: 35252175
[No Abstract] [Full Text] [Related]
18. Divergent clinical outcomes of alpha-glucosidase enzyme replacement therapy in two siblings with infantile-onset Pompe disease treated in the symptomatic or pre-symptomatic state.
Matsuoka T; Miwa Y; Tajika M; Sawada M; Fujimaki K; Soga T; Tomita H; Uemura S; Nishino I; Fukuda T; Sugie H; Kosuga M; Okuyama T; Umeda Y
Mol Genet Metab Rep; 2016 Dec; 9():98-105. PubMed ID: 27896132
[TBL] [Abstract][Full Text] [Related]
19. Effects of enzyme replacement therapy on bone density in late onset Pompe disease.
Avanti M; Martin A; Columbres RC; Mozaffar T; Kimonis V
Mol Genet Metab; 2023 Nov; 140(3):107644. PubMed ID: 37515933
[TBL] [Abstract][Full Text] [Related]
20. Late-onset Pompe disease (LOPD): correlations between respiratory muscles CT and MRI features and pulmonary function.
Gaeta M; Barca E; Ruggeri P; Minutoli F; Rodolico C; Mazziotti S; Milardi D; Musumeci O; Toscano A
Mol Genet Metab; 2013 Nov; 110(3):290-6. PubMed ID: 23916420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
